Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Common Technical Document quality

Draft Guidance. Common Technical Document—Quality Questions and Answers/Location... [Pg.95]

A Sponsor submits a clinical trial application to the Competent Authority in each member state where the trials are to be conducted. The Competent Authority has 60 days to review and approve or reject the application. Application is in prescribed forms and covers the proposed clinical trial protocol, manufacturing, and quality controls on the drug, and supporting data, such as (1) chemical, pharmaceutical, and biological data, (2) nonclinical pharmacological and toxicological data, and (3) clinical data and previous human experience. The supporting data are submitted in the Common Technical Document (CTD) format (see Section 7.11). [Pg.252]

International Conference on Harmonization. The common technical document for the registration of pharmaceuticals for human use quahty, quality overall summary of module 2, module 3 quahty, in Harmonized Tripartite Guideline, ICH, 2002. [Pg.276]

As more than 95% of new medicines are worked out in the ICH regions the technical requirements for the safety, efficacy and quality of new medicines is determined at large by ICH technical guidelines. The application format for registration (marketing authorization) of new medicines in ICH and associated countries (such as Canada, Switzerland and Australia) has to follow The Common Technical Document (CTD) which provides harmonized structure and format for new product applications. This Common Technical Document is divided into four separate sections and 5 modules (see Fig. 1). The four sections address the application organization (M4 Organization), the Quality section (M4Q), the... [Pg.70]

FIGURE 10 Schematic illustration of the ICH M4 common technical document (CTD) the contents of the Quality Overall Summary (2.3) and Quality (3) modules are most relative to PAT. [Pg.334]

If harmonization can be achieved, as it has been, across sufficiently broad areas of quality, safety and efficacy, there is no logical reason why a common technical document (CTD) or dossier cannot be prepared that would be acceptable to all dmg regulatory authorities. Movement to a CTD would appear to be the next step toward further internationalization. [Pg.438]

This chapter has described and discussed the various modules of a Common Technical Document (CTD) as presented in ICH M4. A sponsor preparing a marketing application for submission to any of the three ICH regions and to most other regulatory authorities around the world can, and probably should, utilize the recommend orders of presentation outlined in the ICH CTD guideline for quality, nonclinical, and clinical results generated to support the characterization and development of a drug candidate. [Pg.411]

Efficacy 12 topic headings 16 guidelines Safety 7 topic headings 10 guidelines Quality 7 topic headings 18 guidelines Medical Dictionary MedDRA Electronic Standards ESTRI Timing of Preclinical Studies Common Technical Document CTD... [Pg.172]

Common Technical Document for the Registration of Pharmaceuticals for Human Use (CTD) ICH, 2001) The CTD provides for a harmonized structure, content, and format for new product applications. The document is divided into four separate sections. The four sections address the application organization (M4 organize), the quality section (M4Q), the safety section (M4S) and the efficacy section (M4E) of the harmonized application. Drug metabolism and pharmacokinetic data should be summarized in the safety section that includes the nonclinical overview, nonclinical written summaries, and nonclinical tabulated summaries. More specifically, in Section 2.6.4.S metabolism (interspecies comparison) of the written summaries, the following data should be included ... [Pg.211]

A regulatoiy submission will typically take the form of the Common Technical Document (CTD), which was developed by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Established in 1990, the ICH is a collaboration between the regulatory authorities and pharmaceutical industries of Europe, Japan and the USA their mission is to achieve greater harmonisation to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner. ... [Pg.135]

The Common Technical Document For the Registration of Pharmaceuticals for Human Use Quality—M4q(Rl) Quality Overall Summary of Module 2 Module 3 Quality... [Pg.555]

Accordingly, the final reporting of a fiill performance assessment is an inq>ortant step which needs careful planning. The overview documents must be sufficiently simple and diversified with respect to display material that they can be grasped by a wider audience the back-vp technical documentation must be trace le and of adequate quality to allow review by regulatory authorities or also witiiin the scope of the increasingly common peer reviews at an international level. [Pg.245]


See other pages where Common Technical Document quality is mentioned: [Pg.338]    [Pg.97]    [Pg.347]    [Pg.487]    [Pg.70]    [Pg.84]    [Pg.11]    [Pg.514]    [Pg.3038]    [Pg.4102]    [Pg.5]    [Pg.231]    [Pg.244]    [Pg.446]    [Pg.624]    [Pg.904]    [Pg.515]    [Pg.287]    [Pg.89]    [Pg.338]    [Pg.517]    [Pg.84]    [Pg.1643]    [Pg.734]    [Pg.171]    [Pg.165]    [Pg.904]    [Pg.363]    [Pg.547]    [Pg.9]    [Pg.490]    [Pg.2]    [Pg.2]    [Pg.461]   
See also in sourсe #XX -- [ Pg.559 ]




SEARCH



Quality documentation

Technical documents

© 2024 chempedia.info